NT5E-Targeting Fab Fragments for Tumor-Selective CD73 Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for compositions and methods to target NT5E (CD73) for the detection and treatment of conditions such as cancer, particularly in the tumor microenvironment, while minimizing effects on normal tissues.
Innovation Solution
Development of diverse NT5E-binding proteins, including Fabs and antibodies, which can inhibit NT5E activity selectively on cancer cells, and methods for their use in therapeutic interventions, diagnostics, and functional imaging.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If NT5E is targeted with blocking agents (small molecule inhibitors or monoclonal antibodies), then tumor growth and metastasis are reduced, but there is a risk of affecting normal tissues that also express NT5E
Solution Approach 1:
The patent develops antibody fragments (Fabs) that can penetrate tumor tissue more effectively than full-sized antibodies, enabling localized inhibition of NT5E within the tumor microenvironment while minimizing systemic exposure and off-target effects on normal tissues. The smaller molecular size allows for better tissue penetration and more localized action at the tumor site.
Solution Approach 2:
The patent employs engineered antibody fragments with modified binding affinities and pharmacokinetic properties. By changing the molecular parameters of the therapeutic agent (from full IgG to Fab fragments), the invention achieves enhanced tumor specificity and reduced off-target effects while maintaining therapeutic efficacy against NT5E-expressing cancer cells.
2Reliability
If NT5E is highly overexpressed in cancerous tissues, then it provides a good target for therapy, but the high level of adenosine production creates a protective tumor microenvironment
Solution Approach 1:
The patent converts the high NT5E expression in tumor cells, which normally generates immunosuppressive adenosine, into a therapeutic advantage. By targeting and inhibiting this overexpressed NT5E with Fab fragments, the invention blocks adenosine production and transforms the protective tumor microenvironment into a more immunologically active state that favors anti-tumor immunity.
Solution Approach 2:
The patent applies preliminary inhibition of NT5E activity to prevent the accumulation of immunosuppressive adenosine before it can fully establish a protective tumor microenvironment. By administering NT5E-blocking Fab fragments, the invention preemptively counteracts the tumor's immunosuppressive mechanism, thereby enhancing the effectiveness of subsequent immunotherapies.
3Reliability
If full-sized monoclonal antibodies are used to target NT5E, then potent inhibition is achieved, but tissue penetration and delivery to tumor sites may be limited
Solution Approach 1:
The patent segments the full monoclonal antibody into smaller Fab (antigen-binding fragment) units. This segmentation maintains the antigen-binding and inhibitory potency while reducing the molecular size from ~150 kDa (full IgG) to ~50 kDa (Fab), thereby improving tissue penetration and delivery efficiency to tumor sites without sacrificing therapeutic activity.
Solution Approach 2:
The patent extracts the essential antigen-binding and inhibitory domains from the full monoclonal antibody, discarding the Fc region. This extraction creates Fab fragments that retain potent NT5E inhibition capability while having reduced molecular size and improved pharmacokinetic properties for better tumor tissue penetration and reduced immunogenicity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The NT5E-binding proteins effectively inhibit cancer cell proliferation, invasion, and migration, providing therapeutic benefits while sparing normal tissues, and enable diagnostic and imaging capabilities.
Implementation Method 1
The disclosed potent inhibitory antibodies against NT5E may provide new strategies for therapeutic intervention in conditions such as cancer
Data Source
AI summary
Aspects of the present disclosure are directed to NT5E (CD73)-targeting polypeptides, including antibodies, antibody-drug conjugates, antibody fragments, antibody-like molecules, and chimeric receptors. Also disclosed herein are nucleic acids encoding for such NT5E-targeting polypeptides and cells comprising such nucleic acids. Described are methods for treatment of cancer using NT5E-targeting polypeptides.